Fig. 1: TRIM3 overexpression promotes tamoxifen resistance in breast cancer. | Oncogenesis

Fig. 1: TRIM3 overexpression promotes tamoxifen resistance in breast cancer.

From: Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer

Fig. 1

A A boxplot representing TRIM3 expression levels in ER+ breast cancer with tamoxifen treatment [SD/PD versus CR/PR, P = 0.012, stable disease (SD), progressive disease (PD), complete remission (CR), partial remission (PR)]. B Representative images of TRIM3 expression in recurrence− and recurrence+ ER+ breast cancer tissues with tamoxifen treatment (left panel). Scale bars: 200 μm (upper panel) and 100 μm (lower panel). The statistical significance of the TRIM3 levels is assessed in the right panel. P < 0.05. C Analysis of the effect of TRIM3 expression on Overall Survival (OS), Relapse-Free Survival (RFS), and Distant Metastasis-Free survival (DMFS) of ER+ breast cancer with tamoxifen therapy.

Back to article page